Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • EMPIRICAL-EVALUATION  (10)
  • 1
    Keywords: CANCER ; SURVIVAL ; DIAGNOSIS ; DISEASE ; POPULATION ; AGE ; colorectal cancer ; COLON-CANCER ; MORPHOLOGY ; SUBSITE ; EUROPE ; PATIENT SURVIVAL ; PERIOD ANALYSIS ; colonoscopy ; EMPIRICAL-EVALUATION ; colorectal ; UP-TO-DATE ; EUROCARE-4
    Abstract: BACKGROUND: Colorectal cancer is the most common cancer in Germany and the second most common cause of cancer-related deaths in both men and women. The aim of this study is to provide detailed analysis of recent developments in survival of colorectal cancer patients using newly available data on a national basis. METHODS: We included data from 11 German cancer registries covering a population of 33 million inhabitants. Period analysis and modelled period analysis were used to provide most up-to-date estimates of 5-year relative survival in 2002-2006. RESULTS: The analysis was based on records of 164 996 colorectal cancer patients. Five-year relative survival was 63.0% overall, decreased with age and was significantly higher among women than among men in patients under 75 years. Overall age-adjusted 5-year relative survival increased from 60.6 to 65.0% over the period 2002-2006. Significant increase in survival was only observed in patients with localised or regional disease. Highest subsite-specific survival was observed in patients with cancer in descending (67.7%) and ascending (66.5%) colon. CONCLUSION: Survival of patients with colorectal cancer continued to increase in the early 21st century in Germany, with 5-year relative survival reaching 65% in 2006. However, lack of progress still persisted in patients with advanced disease.
    Type of Publication: Journal article published
    PubMed ID: 22555397
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: POPULATION ; TUMORS ; PATTERNS ; LONG-TERM SURVIVAL ; PROGNOSTIC-FACTORS ; TRENDS ; REGISTRY ; RELATIVE SURVIVAL ; EMPIRICAL-EVALUATION ; UP-TO-DATE
    Abstract: Population-based studies on ovarian cancer providing survival estimates by age, histology, laterality, and stage have been sparse. We aimed to derive the most up-to-date and detailed survival estimates for ovarian cancer patients in Germany. We used a pooled German national dataset including data from 11 cancer registries covering 33 million populations. A total of 21 651 patients diagnosed with ovarian cancer in 1997-2006 were included. Period analysis was carried out to calculate the 5-year relative survival (RS) for the years 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Overall, the age-adjusted 5-year RS in 2002-2006 was 41%. A strong age gradient was observed, with a decrease in the 5-year RS from 67% in the age group 15-49 years to 28% in the age group 70+ years. Furthermore, the prognosis varied markedly by histology, laterality, and stage, with the age-adjusted 5-year RS ranging from 25% (for carcinoma not otherwise specified) to 81% (for stromal cell carcinoma), reaching 46% for unilateral and 32% for bilateral carcinoma and reaching 82% for Federation of Gynecology and Obstetrics (FIGO) stages I and II, 36% for FIGO stage III, and 18% for FIGO stage IV. No improvement in survival could be observed for any of the subgroups in the period between 2002 and 2006. Our analyses suggest that an improvement in the 5-year RS for ovarian cancer may have stagnated in the early 21st century and underline the need for a more effective translation of therapeutic innovation into clinical practice.
    Type of Publication: Journal article published
    PubMed ID: 22694826
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: MODEL ; DISEASE ; chemotherapy ; LONG-TERM SURVIVAL ; OLDER PATIENTS ; PERIOD ANALYSIS ; EMPIRICAL-EVALUATION ; cancer survival ; UP-TO-DATE ; DISPARITIES
    Abstract: Treatment for Hodgkin lymphoma (HL) is more aggressive in Germany than in the United States (US) and differences in treatment may lead to differences in population level survival. Patients diagnosed with HL in 11 German states in 1997-2006 were included in the analyses and were compared to similar analyses from patients in the Surveillance, Epidemiology, and End Results database in the US. Period analysis was used to calculate 5-year relative survival for the time period of 2002-2006 overall and by gender, age and histology. Overall 5-year relative survival for patients with HL in Germany was 84 center dot 3%, compared to 80 center dot 6% for the US. Survival was highest in patients aged 15-29years at 97 center dot 9% and decreased with age to 57 center dot 5% at age 60+ Survival for men and women, respectively, was 84 center dot 7% and 84 center dot 1% in Germany and 78 center dot 2% and 83 center dot 6% in the US. 5-year relative survival for patients diagnosed with HL in Germany was close to 100% for younger patients. Survival of HL patients in the US was lower than in Germany overall, but was comparable in older patients and in women. Population-based studies with longer follow-up are still needed to examine effects of late toxicity on long term survival.
    Type of Publication: Journal article published
    PubMed ID: 24433418
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: MORTALITY ; PROGNOSTIC-FACTORS ; EUROPE ; RECENT TRENDS ; PERIOD ANALYSIS ; CUTANEOUS MALIGNANT-MELANOMA ; THICKNESS ; EMPIRICAL-EVALUATION ; cancer survival
    Abstract: Background Prior analyses of survival of patients with primary cutaneous malignant melanoma from Germany were based only on small populations and need to be updated. Objectives We give a detailed overview of relative 5-year survival by sex, age group, histology, tumour stage and body site, and of time trends in a population of 33 million (40% of Germany), and compare survival in the federal states. Methods Conventional and model-based period analysis using the Ederer II method was applied to patients with melanoma diagnosed during 1997-2006 in Germany to assess 5-year relative survival (RS) rates and time trends. Results In total, 37 155 melanoma cases were included. Overall age-adjusted 5-year RS for the time period 2002-2006 was 91.9% for women and 87.0% for men. Survival differences by age group, histology, tumour stage and body site were found. No significant overall trend (2002-2006) was seen either in women or in men. Differences in survival between federal states were small; no clear pattern was seen. Conclusions Based on the most recent and high-quality data from population-based cancer registries a comprehensive picture on melanoma survival in Germany was given. Survival from cutaneous malignant melanoma was high compared with other cancer sites and did not change during the analysed period 2002-2006. Patterns in melanoma survival by sex, age, tumour stage, histology and body site were in good agreement with previously published findings. No relevant differences between federal states were found.
    Type of Publication: Journal article published
    PubMed ID: 22564081
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: Germany ; AGE ; RATES ; LONG-TERM SURVIVAL ; UNITED-STATES ; PATIENT SURVIVAL ; EMPIRICAL-EVALUATION ; 21ST-CENTURY ; REGISTRY DATA
    Abstract: Background:Period analysis is increasingly used to compute long-term cancer survival, as it provides better prediction of survival of newly diagnosed patients than traditional cohort analysis. However, the patient population to which period survival estimates best pertain to and which should be described in a study is less obvious.Methods:Using Finnish Cancer Registry data on 23 common cancer sites, age-standardized period estimates of 5-, 10-, 15-, and 20-year relative survival were computed for each 2-, 5-, and 10-year calendar period in 1954-2003 and compared with survival estimates for two cohorts by means of mean, mean absolute and mean squared differences: a full cohort of all patients potentially contributing some data to the survival analysis and a restricted cohort of patients diagnosed in the period of interest.Results:In most computations, survival estimates for the full cohorts were on average closer to the period estimates for the majority of cancer sites. For 10-year survival, results were less obvious with respect to the mean difference. However, mean squared and mean absolute differences were smaller for the majority of cancers when using the full cohort.Conclusion:Our results suggest that the full cohort should be described in reports of period survival analysis.
    Type of Publication: Journal article published
    PubMed ID: 23361050
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: FOLLOW-UP ; STAGE ; AGE ; LONG-TERM SURVIVAL ; TRENDS ; EUROPE ; PERIOD ANALYSIS ; ELDERLY-WOMEN ; EMPIRICAL-EVALUATION ; UP-TO-DATE
    Abstract: Population-based survival studies of breast cancer patients are commonly restricted to age- and stage-specific analyses. This study from Germany aimed at extending available population-based survival data on further prognostic cancer characteristics such as tumor grade, hormone receptor status and human epidermal growth factor receptor type 2 (HER2/neu) expression. Data from the population-based Saarland Cancer Registry including female patients diagnosed with invasive breast cancer between 2000 and 2009 were included. Period analysis methodology and regression modelling were used to obtain estimates of 5-year relative survival and tumor related excess risks in 2005-2009. Overall age standardized 5-year relative survival was 83%. In addition to age and stage, tumor grade and hormone receptor status were independent predictors of 5-year relative survival. Detailed analyses by age, stage, morphology, tumor grade, hormone receptor status and HER2/neu expression consistently revealed lower survival of patients with high grade, hormone receptor negative or HER2/neu positive cancers and patients aged 70 years or older. This high resolution study extends available population-based survival data of breast cancer patients. Particular efforts should be made to overcome the persisting large survival deficits, which were observed for elderly patients in all clinical subgroups.
    Type of Publication: Journal article published
    PubMed ID: 23936237
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: POPULATION ; prognosis ; LONG-TERM SURVIVAL ; HUMAN-PAPILLOMAVIRUS ; EUROPE ; WORLDWIDE ; METAANALYSIS ; EMPIRICAL-EVALUATION ; UP-TO-DATE ; CHEMORADIOTHERAPY
    Abstract: Purpose. Population-based studies on cervical cancer providing survival estimates by age, histology, and stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for cervical cancer patients in Germany. Methods. We used a pooled German national dataset including data from 11 cancer registries covering a population of 33 million people. Included were 15 685 patients diagnosed with cervical cancer from 1997 to 2006. Period analysis was performed to calculate the five-year relative survival (RS) 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age-adjustment was done using five age groups (15-44, 45-54, 55-64, 65-74, and 75 + years). Results. Overall, age-adjusted five-year relative survival in 2002-2006 was 64.7%. A strong age gradient was observed, with five-year RS decreasing from 81.7% in age group 15-49 years to 46.3% in age group 70 + years. Prognosis furthermore strongly varied by stage, with age-adjusted five-year RS reaching 84.6% for localized, 48.2% for regional, and 17.9% for distant stage. From 2002 to 2006, a significant improvement (4.7 percent units) in overall age-adjusted five-year RS was seen. The improvement was most pronounced for age groups 55-64 years (from 54.2 to 65.6%) and 65-74 years (from 50.0 to 58.1%). Conclusion. In this first comprehensive population-based study from Germany, prognosis of cervical cancer strongly varied by age and stage. Prognosis continued to improve, in particular in age range 55-74 years, in the five-year period assessed.
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    Keywords: CANCER ; SURVIVAL ; Germany ; STAGE ; LONG-TERM SURVIVAL ; PROGNOSTIC-SIGNIFICANCE ; ENDOMETRIAL CANCER ; POSTMENOPAUSAL WOMEN ; cancer registries ; PERIOD ANALYSIS ; EMPIRICAL-EVALUATION ; ENDOGENOUS HORMONES ; UP-TO-DATE ; ESTROGEN-RECEPTOR-ALPHA ; ER-ALPHA ; SOCIETY GUIDELINES ; Population based ; UTERINE SARCOMAS
    Abstract: Background: Population-based studies on endometrial cancer providing survival estimates by age, histology, and stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial cancer patients in Germany. Methods: We used a pooled German national dataset including data from 11 cancer registries covering a population of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included. Period analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Results: Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was observed, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years. Furthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from 43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for distant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent 5-year period under investigation. Conclusion: In this comprehensive population-based survival analysis of patients with endometrial cancer from Germany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage. While prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer patients has been stagnating in the early 21st century
    Type of Publication: Journal article published
    PubMed ID: 22459016
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    Keywords: CANCER ; POPULATION ; LONG-TERM SURVIVAL ; UNITED-STATES ; B-CELL LYMPHOMA ; PERIOD ANALYSIS ; rituximab ; EMPIRICAL-EVALUATION ; UP-TO-DATE ; LOW-GRADE
    Abstract: Abstract This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age 75+. Survival in the US was 75.3% at age 15-49 and 52% at age 75+. Survival was higher for women than for men, at 65.2% for women and 60.7% for men. Survivals for diffuse B-cell lymphoma and follicular lymphoma, the two most common subtypes of NHL, were 57.3% and 77.5%, respectively. Between 2002 and 2006, overall 5-year relative survival increased by 5.3 percentage points. We conclude that survival for NHL is increasing in Germany in recent years. Survival was higher in Germany than in the US for patients aged 15-49 but lower for older patients.
    Type of Publication: Journal article published
    PubMed ID: 23098058
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: THERAPY ; DIAGNOSIS ; TRIAL ; CHILDREN ; TRENDS ; PERIOD ANALYSIS ; EMPIRICAL-EVALUATION ; UP-TO-DATE ; CANCER-PATIENT SURVIVAL ; EARLY 21ST-CENTURY
    Abstract: Background: Adulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level. Methods: Data were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate 5-year relative survival (RS). Results: Overall 5-year RS was estimated at 43.4% for Germany and 35.5% for the US (p = 0.004), with a decrease in survival with increasing age. Survival was higher in Germany than the US for men (43.6% versus 37.7%, p = 0.002) but not for women (42.4% versus 40.3%, p 〉 0.1). Five-year RS estimates increased in Germany and the US between 2002 and 2006 by 11.8 and 7.3 percent units, respectively (p = 0.02 and 0.04, respectively). Conclusions: Survival for adults with ALL continues to be low compared with that for children, but a substantial increase in 5-year survival estimates was seen from 2002 to 2006 in both Germany and the US. The reasons for the survival differences between both countries require clarification.
    Type of Publication: Journal article published
    PubMed ID: 24475044
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...